OOIR: Observatory of International Research

Papers

(The H4-Index of Future Oncology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	99
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	84
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	67
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	67
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	63
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	62
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	59
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	56
Sex bias phenomenon in oral cancer: an insight	45
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	45
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	43
ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer	42
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	41
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	40
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	40
Correction	38
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	38
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC	38
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	37
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	37
Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors	37
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study	36
Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design)	36
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	35
Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China	34

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols	34
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	34
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	33
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	33
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	32